Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus.
FSHB/FSHR
LHB/LHCGR
assisted reproductive technology (ART)
genetic variants
genetics
gonadotropins
ovarian stimulation and response
single nucleotide polymorphisms (SNPs)
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
10
2021
accepted:
15
12
2021
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
1
4
2022
Statut:
epublish
Résumé
A Delphi consensus was conducted to evaluate the influence of single nucleotide polymorphisms (SNPs) in genes encoding gonadotropin and gonadotropin receptors on clinical ovarian stimulation outcomes following assisted reproductive technology (ART) treatment. Nine experts plus two Scientific Coordinators discussed and amended statements plus supporting references proposed by the Scientific Coordinators. The statements were distributed Eleven statements were developed, of which two statements were merged. Overall, eight statements achieved consensus and two statements did not achieve consensus. The statements reaching consensus are summarized here. (1) SNP in the follicle stimulating hormone receptor ( This Delphi consensus provides clinical perspectives from a diverse international group of experts. The consensus supports a link between some variants in gonadotropin/gonadotropin receptor genes and ovarian stimulation outcomes; however, further research is needed to clarify these findings.
Sections du résumé
Background
A Delphi consensus was conducted to evaluate the influence of single nucleotide polymorphisms (SNPs) in genes encoding gonadotropin and gonadotropin receptors on clinical ovarian stimulation outcomes following assisted reproductive technology (ART) treatment.
Methods
Nine experts plus two Scientific Coordinators discussed and amended statements plus supporting references proposed by the Scientific Coordinators. The statements were distributed
Results
Eleven statements were developed, of which two statements were merged. Overall, eight statements achieved consensus and two statements did not achieve consensus. The statements reaching consensus are summarized here. (1) SNP in the follicle stimulating hormone receptor (
Conclusions
This Delphi consensus provides clinical perspectives from a diverse international group of experts. The consensus supports a link between some variants in gonadotropin/gonadotropin receptor genes and ovarian stimulation outcomes; however, further research is needed to clarify these findings.
Identifiants
pubmed: 35178027
doi: 10.3389/fendo.2021.797365
pmc: PMC8844496
doi:
Substances chimiques
Chorionic Gonadotropin
0
Follicle Stimulating Hormone, beta Subunit
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
797365Informations de copyright
Copyright © 2022 Conforti, Tüttelmann, Alviggi, Behre, Fischer, Hu, Polyzos, Chuderland, Rama Raju, D’Hooghe, Simoni, Sunkara and Longobardi.
Déclaration de conflit d'intérêts
The Delphi consensus was coordinated by a healthcare consulting and training company (Sanitanova Srl, Milan, Italy). The consensus concept was initiated and funded by Merck KGaA, Darmstadt, Germany. The sponsor was involved early in the process, defining the overarching topic to be discussed, but did not participate in the development of the statements or in any of the meetings or discussions involved in developing the Delphi consensus. The statements were, therefore, developed independently of the industry sponsor. The authors from Merck KGaA, Darmstadt, Germany, were only involved in the development of the manuscript, critically revising it for important intellectual content, especially in the Introduction, Results and Discussion sections, but could not alter the consensus statements in any way. DC, TD’H, and SL are employees of Merck KGaA, Darmstadt, Germany. AC has received of honoraria and consultation from Merck KGaA, Darmstadt, Germany and Event Planet SpA. CA has received of honoraria for lectures from Merck KGaA, Darmstadt, Germany and Event Planet SpA. HB has been scientific advisor for Merck KGaA, Darmstadt, Germany and MSD. RF has received honoraria from Merck KGaA, Darmstadt, Germany and affiliates for lectures. NP received research grants or honoraria for lectures from: Merck KGaA, Darmstadt, Germany, MSD, Ferring Pharmaceuticals, Besins International, Roche Diagnostics, IBSA, Theramex, Gedeon Richter. MS received honoraria and research grants from Merck KGaA, Darmstadt, Germany, Ferring and IBSA. SS was a speaker at non-promotional educational symposia by Merck KGaA, Darmstadt, Germany and Ferring, and received independent research grants from Merck KGaA, Darmstadt, Germany and Ferring. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Reprod Sci. 2016 Aug;23(8):1103-8
pubmed: 26902430
J Dermatolog Treat. 2015 Apr;26(2):128-33
pubmed: 24708158
Hum Reprod Update. 2006 Nov-Dec;12(6):685-718
pubmed: 16891297
Panminerva Med. 2019 Mar;61(1):24-29
pubmed: 30021418
J Assist Reprod Genet. 2019 Jan;36(1):29-38
pubmed: 30232643
Fertil Steril. 2019 Sep;112(3):520-526.e1
pubmed: 31227285
Eur J Intern Med. 2014 Oct;25(8):751-6
pubmed: 25123424
Hum Reprod. 2013 May;28(5):1369-74
pubmed: 23504007
J Clin Endocrinol Metab. 2013 Jan;98(1):E82-6
pubmed: 23118424
Hum Reprod. 2018 May 1;33(5):954-966
pubmed: 29617818
Am J Obstet Gynecol. 2017 Aug;217(2):129-140
pubmed: 28235465
PLoS One. 2013 Oct 22;8(10):e78138
pubmed: 24167601
Reprod Biomed Online. 2011 Feb;22 Suppl 1:S73-82
pubmed: 21575853
Mol Hum Reprod. 2002 Oct;8(10):893-9
pubmed: 12356937
Pharmacogenet Genomics. 2005 Jul;15(7):451-6
pubmed: 15970792
Pharmacogenet Genomics. 2019 Jul;29(5):114-120
pubmed: 30829738
Fertil Steril. 2021 Sep;116(3):741-756
pubmed: 33926722
Science. 2007 Jan 26;315(5811):525-8
pubmed: 17185560
Hum Reprod Open. 2020 Jul 31;2020(3):hoaa032
pubmed: 32760812
Pharmacogenomics. 2014 Apr;15(6):885-93
pubmed: 24897293
J Assist Reprod Genet. 2017 Dec;34(12):1659-1666
pubmed: 28825151
Eur J Endocrinol. 2014 Feb 04;170(3):R91-107
pubmed: 24288354
J Assist Reprod Genet. 2006 Apr;23(4):177-84
pubmed: 16758348
Pharmacogenetics. 2004 May;14(5):285-93
pubmed: 15115914
BMC Cancer. 2019 Apr 16;19(1):359
pubmed: 30991970
Front Endocrinol (Lausanne). 2019 Jun 27;10:387
pubmed: 31316461
Fertil Steril. 2005 Aug;84(2):446-53
pubmed: 16084888
Fertil Steril. 2018 Apr;109(4):644-664
pubmed: 29653717
Clin Endocrinol (Oxf). 2015 Apr;82(4):577-83
pubmed: 25132286
Hum Reprod. 2021 May 17;36(6):1711-1721
pubmed: 33889959
Reprod Biol Endocrinol. 2018 Oct 19;16(1):100
pubmed: 30340493
Fertil Steril. 2018 Sep;110(4):661-670.e1
pubmed: 30196963
Fertil Steril. 2001 Dec;76(6):1185-90
pubmed: 11730748
Front Endocrinol (Lausanne). 2021 May 11;12:628169
pubmed: 34046009
Horm Res. 2001;55(5):258-63
pubmed: 11740150
Hum Reprod. 2020 Dec 1;35(12):2832-2849
pubmed: 33188410
Fertil Steril. 2019 Mar;111(3):477-488
pubmed: 30737003
PLoS One. 2012;7(6):e38700
pubmed: 22701696
Fertil Steril. 2010 Feb;93(2):382-90
pubmed: 19081561
Front Endocrinol (Lausanne). 2019 Jun 26;10:398
pubmed: 31293516
Fertil Steril. 2021 Jun;115(6):1430-1431
pubmed: 34053513
J Hum Genet. 2006;51(8):665-670
pubmed: 16871362
Acta Obstet Gynecol Scand. 2005 Aug;84(8):806-11
pubmed: 16026410
J Ovarian Res. 2014 Dec 20;7:285
pubmed: 25526787
Hum Reprod. 2016 Mar;31(3):672-83
pubmed: 26769719
Fertil Steril. 2016 Jun;105(6):1452-3
pubmed: 26921622
Cell. 1995 Sep 22;82(6):959-68
pubmed: 7553856
Hum Reprod Update. 2014 Jul-Aug;20(4):560-70
pubmed: 24532220
Hum Reprod Update. 2011 Nov-Dec;17(6):813-28
pubmed: 21862569
PLoS One. 2016 Mar 07;11(3):e0149615
pubmed: 26950065
Curr Opin Obstet Gynecol. 2010 Jun;22(3):189-92
pubmed: 20216414
Hum Reprod. 2011 Jul;26(7):1768-74
pubmed: 21558332
Reprod Biomed Online. 2009 Apr;18(4):509-15
pubmed: 19400992
Front Endocrinol (Lausanne). 2021 Mar 19;12:587051
pubmed: 33815269
Hum Reprod. 2021 Jul 19;36(8):2157-2169
pubmed: 34179973
Aging (Albany NY). 2019 Dec 2;11(23):10952-10991
pubmed: 31790362
Fertil Steril. 2003 Oct;80(4):986-92
pubmed: 14556822
Med Arch. 2016 Oct;70(5):364-368
pubmed: 27994298
Cell Physiol Biochem. 2014;34(5):1527-35
pubmed: 25322982
J Assist Reprod Genet. 2015 Dec;32(12):1801-10
pubmed: 26481502
Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:119-125
pubmed: 29408742
Hum Reprod Update. 2018 Sep 1;24(5):599-614
pubmed: 29924306
Gene. 2014 Oct 15;550(1):68-73
pubmed: 25111116
Fertil Steril. 2009 Feb;91(2):432-9
pubmed: 18321487
Reproduction. 2013 Oct 23;146(6):R235-48
pubmed: 24051057
Biochim Biophys Acta. 2014 Oct;1842(10):1910-1922
pubmed: 24667321
Genet Test Mol Biomarkers. 2019 Jan;23(1):39-44
pubmed: 30585745
J Clin Endocrinol Metab. 2000 Sep;85(9):3365-9
pubmed: 10999835
J Assist Reprod Genet. 2012 Nov;29(11):1185-91
pubmed: 22915343
Fertil Steril. 2003 Sep;80(3):571-6
pubmed: 12969700
Fertil Steril. 2020 Apr;113(4):761-762
pubmed: 32151348
Reprod Biol Endocrinol. 2013 Jun 01;11:51
pubmed: 23725475
Hum Reprod. 2021 May 17;36(6):1469-1480
pubmed: 33792685
J Manag Care Spec Pharm. 2016 Oct;22(10):1107-13
pubmed: 27668559
Front Endocrinol (Lausanne). 2018 Oct 17;9:589
pubmed: 30386293
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Reprod Biomed Online. 2011 Feb;22 Suppl 1:S67-72
pubmed: 21575852
J Clin Endocrinol Metab. 2011 Sep;96(9):2805-12
pubmed: 21752882
Front Endocrinol (Lausanne). 2019 Feb 20;10:94
pubmed: 30842755
Hum Reprod Update. 2014 Sep-Oct;20(5):688-701
pubmed: 24821925
J Hum Reprod Sci. 2011 May;4(2):86-90
pubmed: 22064672
Fertil Steril. 2018 Apr;109(4):608-609
pubmed: 29653708